Considerable Shareholder Wei Fu Increases Shareholding in Everest Medicines Again, Marking His Second Share Purchase in 2026 and Demonstrating Long-term Confidence

HONG KONG, May 15, 2026 – (ACN Newswire) –Everest Medicines (HKEX: 1952. HK) revealed that on 14 May 2026, based upon strong self-confidence in the business’s future potential customers and long-lasting advancement, Mr. Wei Fu, a non-executive Director, the honorary chairman of the Board and a significant investor of the business, bought 660,000 normal shares of the business on the open-market for an overall factor to consider of roughly HK$ 20.7 million, representing a typical cost of around HK$ 31.25 per Share. Mr. Wei Fu mentioned that he does not dismiss the possibility of more increasing his shareholdings in the business when proper.

This marks Mr. Wei Fu’s 2nd share purchase in Everest Medicines in 2026. Formerly, on March 27, he obtained 860,000 shares of Everest Medicines at a typical cost of around HK$ 38.12 per share, for an overall factor to consider of roughly HK$ 32.7 million.

Mr. Wei Fu’s successive share purchases within the year show his company self-confidence in both Everest Medicines’ tactical instructions and functional accomplishments. At the end of 2025, Everest Medicines revealed its 2030 method, which plainly embraces a dual-engine technique driven by both service advancement partnerships and internal R&D. By 2030, the business intends to accomplish earnings going beyond RMB15 billion and broaden its commercialized item portfolio to more than 20 items, while continuing to concentrate on high-growth restorative locations consisting of nephrology, cardiovascular and metabolic illness. In December 2025, the management group and significant investors jointly increased their shareholdings in the market, indicating long-lasting self-confidence in the business’s advancement.

On the functional front, Everest Medicines reported overall income of RMB1.707 billion for the complete year of 2025, representing a year-over-year boost of 142%. The business likewise attained yearly success for the very first time on a non-IFRS basis, taping a revenue of RMB187 million, while running capital turned favorable in the 4th quarter. Sales profits of NEFECON ® reached RMB1.443 billion, representing development of more than 300% year-over-year, making it the very first non-oncology ingenious drug in China to go beyond RMB1 billion in yearly sales in its very first year of addition in the National Reimbursement Drug List (NRDL). XERAVA ® attained sales earnings of RMB262 million, with in-hospital sales increasing by 44% year-over-year. These outcomes even more confirm the business’s enhancing commercialization abilities and continued execution momentum.

The management group’s cumulative shareholding boosts and Mr. Fu’s successive share purchases in 2026 showed strong self-confidence in the Company’s long-lasting potential customers. Supported by strong functional execution and tactical execution, Everest Medicines’ medium- to long-lasting development trajectory is ending up being progressively clear.

Subject: Press release summary